An Inhibition of the Hypothalamic Somatostatinergic Tone is not the Cause of the Enhanced Growth Hormone Response to Growth Hormone-Releasing Hormone in Patients with Liver Cirrhosis

Abstract

Animal models of liver cirrhosis (LC) display a reduced hypothalamic somatostatinergic tone. To test whether a similar mechanism could explain the enhanced Growth Hormone (GH) secretory response to GH-Releasing Hormone (GHRH), which is seen in human LC, we studied the effect of the cholinesterase inhibitor pyridostigmine (PD), which is able to reduce the release of hypothalamic somatostatin (SS), on the GHRH-stimulated GH secretion. We considered that if PD were unable to increase GH secretion, this would constitute evidence of an already inhibited endogenous somatostatinergic tone. If proved, this in turn could explain the enhanced GH response to GHRH seen in LC. Ten LC patients and nine controls were given GHRH (100 μg, intravenously), or PD (120 mg, orally) plus GHRH. After GHRH alone, the GH peak was four times higher in LC than in controls (40.85±15.7 ng/ml in LC and 9.35±2.5 ng/ml in controls). In LC, PD administration markedly increased the GH response to GHRH (GH peak: 98.0±19.7 ng/ml; +240% vs. GHRH alone). The ability of PD to increase the GH response in patients with LC suggests that in this condition the enhanced GH response to GHRH is not due to a completely inhibited endogenous somatostatinergic tone. SS appears instead to maintain its modulator role on GH secretion in human LC, in contrast with what observed in animal models.

Key words

Growth Hormone - Growth Hormone-Releasing Hormone - hypothalamus - liver cirrhosis - pituitary - somatostatin

References

• 1 Aimaretti G, Baffoni C, DiVito L, Bellone S, Grottoli S, Maccario M, Arvat E, Camanni F, Ghigo E. Comparisons among old and new provocative tests of GH secretion in 178 normal adults.  Eur J Endocrinol. 2000;  142 347-352
• 2 Baruch Y, Assy N, Amit T, Krivoy N, Strickovsky D, Orr ZS, Hochberg Z. Spontaneous pulsatility and pharmacokinetics of growth hormone in liver cirrhotic patients.  J Hepatol. 1998;  29 559-564
• 3 Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu L, Hintz RL. Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary.  Science. 1981;  212 1279-1281
• 4 Broglio F, Gottero C, Benso A, Prodam F, Casanueva FF, Dieguez C, Lely AJ van der, Deghenghi R, Arvat E, Ghigo E. Acetylcholine does not play a major role in mediating the endocrine responses to ghrelin, a natural ligand of the GH secretagogue receptor, in humans.  Clin Endocrinol (Oxf). 2003;  58 92-98
• 5 Ceda GP, Davis RG, Rosenfeld RG, Hoffman AR. The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II.  Endocrinology. 1987;  120 1658-1662
• 6 Broglio F, Gottero C, Koetsveld P Van, Prodam F, Destefanis S, Benso A, Gauna C, Hofland L, Arvat E, Lely AJ van der, Ghigo E. Acetylcholine regulates ghrelin secretion in humans.  J Clin Endocrinol Metab. 2004;  89 2429-2433
• 7 Camina JP, Carreira MC, Micic D, Pombo M, Kelestimur F, Dieguez C, Casanueva FF. Regulation of ghrelin secretion and action.  Endocrine. 2003;  22 5-12
• 8 Castilla-Cortazar I, Aliaga-Montilla MA, Salvador J, Garcia M, Delgado G, Gonzalez-Baron S, Quiroga J, Prieto J. Insulin-like growth factor-I restores the reduced somatostatinergic tone controlling growth hormone secretion in cirrhotic rats.  Liver. 2001;  21 405-409
• 9 Caufriez A, Reding P, Urbain D, Golstein J, Copinschi G. Insulin-like growth factor I: a good indicator of functional hepatocellular capacity in alcoholic liver cirrhosis.  J Endocrinol Invest. 1991;  14 317-321
• 10 Child CG, Turcott JG. Surgery and portal hypertension. In: Child CG (ed). The liver and portal hypertension. Philadelphia: WB Saunders Co. 1964: 50-76
• 11 Chopra IJ, Tulchinsky D, Greenway FL. Estrogen-androgen imbalance in hepatic cirrhosis Studies in 13 male patients.  Ann Intern Med. 1973;  79 198-203
• 12 Cuneo RC, Hickman PE, Wallace JD, Teh BT, Ward G, Veldhuis JD, Waters MJ. Altered endogenous growth hormone secretory kinetics and diurnal GH-binding protein profiles in adults with chronic liver disease.  Clin Endocrinol (Oxf). 1995;  43 265-275
• 13 Delitala G, Tomasi P, Virdis R. Neuroendocrine regulation of human growth hormone secretion. Diagnostic and clinical applications.  J Endocrinol Invest. 1988;  11 441-462
• 14 Galvao-Teles A, Burke CW, Anderson DC, Marshall JC, Corker CS, Bown RL, Clark ML. Biologically active androgens and oestradiol in men with chronic liver disease.  Lancet. 1973;  1 173-177
• 15 Ghigo E, Goffi S, Arvat E, Imperiale E, Boffano GM, Valetto MR, Mazza E, Santi I, Magliona A, Boghen MF, Boccuzzi G, Camanni F. A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging.  J Endocrinol Invest. 1992;  15 665-670
• 16 Gianotti L, Broglio F, Aimaretti G, Arvat E, Colombo S, Di Summa M, Gallioli G, Pittoni G, Sardo E, Stella M, Zanello M, Miola C, Ghigo E. Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions.  J Endocrinol Invest. 1998;  21 115-121
• 17 Hattori N, Kurahachi H, Ikekubo K, Ishihara T, Moridera K, Hino M, Saiki Y, Imura H. Serum growth hormone-binding protein, insulin-like growth factor-I, and growth hormone in patients with liver cirrhosis.  Metabolism. 1992;  41 377-381
• 18 Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach.  Nature. 1999;  402 656-660
• 19 Massara F, Ghigo E, Demislis K, Tangolo D, Mazza E, Locatelli V, Muller EE, Molinatti GM, Camanni F. Cholinergic involvement in the growth hormone releasing hormone-induced growth hormone release: studies in normal and acromegalic subjects.  Neuroendocrinology. 1986;  43 670-675
• 20 Pittoni G, Gallioi G, Zanello M, Gianotti L, Boghen MF, Colombo S, Broglio F, Santoro C, Davia G, Papini MG, Destefanis S, Minuto F, Miola C, Ghigo E. Activity of GH/IGF-I axis in trauma and septic patients during artificial nutrition: different behavior patterns?.  J Endocrinol Invest. 2002;  25 214-223
• 21 Ross RJ, Tsagarakis S, Grossman A, Nhagafoong L, Touzel RJ, Rees LH, Besser GM. GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH.  Clin Endocrinol (Oxf). 1987;  27 727-733
• 22 Salerno F, Locatelli V, Muller EE. Growth hormone hyperresponsiveness to growth hormone-releasing hormone in patients with severe liver cirrhosis.  Clin Endocrinol (Oxf). 1987;  27 183-190
• 23 Tzanela M, Karavitaki N, Stylianidou C, Tsagarakis S, Thalassinos NC. Assessment of GH reserve before and after successful treatment of adult patients with Cushing's syndrome.  Clin Endocrinol (Oxf). 2004;  60 309-314
• 24 Tzanela M, Zianni D, Stylianidou Ch, Karavitaki N, Tsagarakis S, Thalassinos NC. Evaluation of GH reserve in patients with adrenal incidentalomas and biochemical evidence of subclinical autonomous glucocorticoid hypersecretion.  Clin Endocrinol (Oxf). 2005;  62 597-602
• 25 Zietz B, Lock G, Plach B, Drobnik W, Grossmann J, Scholmerich J, Straub RH. Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis.  Eur J Gastroenterol Hepatol. 2003;  15 495-501

Correspondence